The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

March 31, 2011

Study Completion Date

May 31, 2012

Conditions
Bladder Cancer
Interventions
DRUG

Gemcitabine 2 g

six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline

DRUG

BCG Vaccine

six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline

Trial Locations (1)

10126

A.O.U. San Giovanni Battista Molinette, Torino

All Listed Sponsors
collaborator

University of Turin, Italy

OTHER

collaborator

Universitätsklinikum Hamburg-Eppendorf

OTHER

collaborator

University of Eastern Piedmont

OTHER

lead

A.O.U. Città della Salute e della Scienza

OTHER

NCT01697306 - The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer | Biotech Hunter | Biotech Hunter